Answers are grounded in this paper and cite their sources.
Fluorene-9-bisphenol (BHPF; 9,9-bis(4-hydroxyphenyl)fluorene) is used in “BPA-free” plastic products, and its endocrine-disrupting activities have been suggested mainly in fish models. However, guideline-relevant evidence regarding prenatal developmental toxicity in mammals remains limited. We conducted a prenatal developmental toxicity study based on OECD TG 414 in mice to provide hazard characterization of BHPF. Pregnant ICR mice were orally administered BHPF at 3.75 or 37.5 mg/kg bw/day from gestation day (GD) 5.5 to GD17.5 and examined on GD18.5. The high dose was set at the maximum feasible dose, based on the highest BHPF concentration that could be stably dissolved in the dosing vehicle. BHPF caused no treatment-related adverse effects on maternal survival, clinical signs, body weight gain, or pregnancy outcomes. Thyroid-related endpoints included in the updated OECD TG 414, including thyroid histopathology and serum thyroid-related hormones, were evaluated and showed no treatment-related findings suggestive of maternal hypothyroidism. Serum biochemical markers were largely comparable to controls. External, visceral, and skeletal examinations revealed no treatment-related adverse effects on fetal development. Overall, no adverse signals for prenatal developmental toxicity or maternal thyroid-related disruption were observed at the solubility-/feasibility-limited high dose, providing guideline-relevant mammalian data indicating an endpoint-specific NOAEL for these endpoints under the present study conditions.
No takes yet. Share an insight, caveat, or question.
Ishida et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: